SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is drawing attention after a sharp semiconductor-sector selloff, fueled by supply-chain concerns flagged by LAM Research and broader doubts about AI spending and chip valuations; its 3x leverage magnifies the decline. Traders are split between buying an oversold dip and expecting further losses, with many warning that volatility could remain high.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energys strong Q3 results and raised outlook were overshadowed by a sharp share decline, with traders focused on negative cash flow, heavy investment spending and valuation concerns amid weakness in AI-linked stocks. Bulls called the selloff an overreaction and looked to buy the dip, while bears argued the price had run ahead of fundamentals.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokias Q3 results beat expectations, but shares sold off sharply as traders focused on reduced free-cash-flow conversion guidance, negative cash flow, higher restructuring costs and managements warning of structural supply-cost inflation. Bulls see the drop as an overreaction given strong AI and cloud demand, while bears argue cash generation concerns outweigh the earnings beat.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. It operates through the Hard Disk Drives (HDD) segment. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Western Digitals strong quarterly results and upbeat outlook have been overshadowed by a sharp share-price decline, prompting debate over whether investors are pricing in elevated spending, peak-cycle earnings and broader weakness in AI-linked stocks. Bulls point to durable AI-driven storage demand and pricing strength, while bears question how sustainable the cycle is.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following segments: Walmart U.S., Walmart International, and Sam's Club U.S. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club U.S. segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmarts sharp rally is drawing attention after Deutsche Bank upgraded the stock to Buy, citing a more favorable outlook and potential for improving margins; traders are also pointing to defensive-sector flows amid weakness in technology stocks. Bulls are leaning into the momentum and call buying, while bears argue the valuation is stretched and the move could reverse if money rotates back to tech.

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

Trading-platform outages and Thinkorswim login, order-entry, and pricing problems are driving the discussion, with traders frustrated about being unable to manage positions and some considering moving their accounts to other brokers. Complaints are widespread, though a few users report that access was restored or that their platforms were working.

Forgent Power Solutions, Inc. is a holding company, which engages in the design and manufacture of electrical distribution equipment used in data centers, power grid, and energy-intensive industrial facilities. It also offers powertrain solutions and standard and custom products. The company was founded on July 21, 2025 and is headquartered in Dayton, MN.

Forgent Power Solutions Inc. - Ordinary Shares - Class A

Forgent Power Solutions Inc.

CFO Ryan Fiedlers departure triggered a sharp selloff, with some traders speculating about undisclosed financial problems while others called the reaction excessive. The company said the departure involved no disagreement and indicated first-quarter revenue and adjusted EBITDA would exceed the high end of guidance, prompting debate over whether strong business trends outweigh lingering uncertainty.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

A sharp Nasdaq- and technology-led selloff has weighed on TQQQ, with traders pointing to inflation and interest-rate worries alongside concerns about AI spending and chip stocks. The community is split between buying an oversold dip for a relief bounce and warning that bearish momentum could bring further losses, amplified by the funds 3x daily leverage.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas Phase 3 melanoma-vaccine results leaked ahead of the ESMO presentation, triggering a sharp selloff despite showing reduced recurrence risk when the vaccine was combined with Keytruda. Traders are divided between calling it a sell-the-news reaction after a steep run-up and arguing that the results fell short of elevated expectations, with uncertainty about commercial prospects and efficacy beyond melanoma.

Deckers Outdoor Corp. engages in the business of designing, marketing, and distributing footwear, apparel, and accessories developed for both everyday casual lifestyle use and high performance activities. It operates through the following segments: UGG Brand, HOKA Brand, Teva Brand, Sanuk Brand, Other Brands, and Direct-to-Consumer. The UGG Brand segment offers a line of premium footwear, apparel, and accessories. The HOKA Brand segment sells footwear and apparel that offers enhanced cushioning and inherent stability with minimal weight, originally designed for ultra-runners. The Teva Brand segment focuses on the sport sandal and modern outdoor lifestyle category, such as sandals, shoes, and boots. The Sanuk Brand segment originated in Southern California surf culture and has emerged into a lifestyle brand with a presence in the relaxed casual shoe and sandal categories. The Other Brands segment includes the Koolaburra by UGG brand. The Direct-to-Consumer segment consists of retail stores and e-commerce websites. The company was founded by Douglas B. Otto in 1973 and is headquartered in Goleta, CA.

Deckers Outdoor Corp.

Deckers quarterly results and reduced sales outlook are driving attention: earnings beat expectations, but revenue missed and management cited price-conscious shoppers, heavier promotions, and slower HOKA and UGG growth. Traders are divided between calling the selloff excessive given strong margins and buybacks and worrying that footwear demand and growth are weakening.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?

Equity

Shares of Kodiak Sciences, Repligen, and Biogen surged to annual highs amid positive company catalysts.

Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study

MRK's remigromig meets the primary goal in a DME study, showing non-inferiority to ranibizumab while further safety analyses continue.

AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study

Amgen's dazodalibep meets its primary goal in a Phase III study, showing sustained improvement in systemic Sjogren's disease activity through week 48.

Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290

ALKS posts positive Phase I data for ALKS 7290, showing meaningful improvements in ADHD symptoms across dose levels in healthy volunteers and adults.

JNJ's Caplyta Shows Benefit in Bipolar 1 Related Mania Study

J&J's Caplyta shows rapid and significant improvement in bipolar mania symptoms in a pivotal phase III study.

NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication 

NVS' Cosentyx wins a positive EU opinion for PMR, backed by late-stage data, potentially expanding its use beyond existing inflammatory conditions.

Merck Gets CHMP Backing for Keytruda-Padcev Combo in Bladder Cancer

MRK's Keytruda plus Padcev combo gets CHMP backing as perioperative treatment for eligible patients with resectable muscle-invasive bladder cancer.

CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer

Corcept's Lifyorli plus nab-paclitaxel wins a positive CHMP opinion for platinum-resistant ovarian cancer, with an EC decision expected in Q4 2026.

PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins

Puma Biotechnology starts the ALISCA-Lung2 phase II study evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer.

RHHBY's Lunsumio Combo Meets Goal in 2L Follicular Lymphoma Study

Roche's Lunsumio-Revlimid combo meets its study goal in second-line or later follicular lymphoma, improving PFS versus rituximab plus Revlimid.

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Repligen Corp.

Neutral Sentiment

<ul class="summary-bullets"><li><a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a> stock surged more than 177% at close after it said that its experimental drugs, Zenkuda and KSI-501, had met the primary endpoints in its Phase 3 Daybreak trial.</li><li>RGEN stock gained more than 2% at close, extending gains amid positive investor sentiment following its strong second-quarter 2026 earnings beat, increased full-year financial guidance, and expansion into cell therapy.</li><li>BIIB stock gained about 0.5% at close on Monday amid a buy-in following its strong second-quarter 2026 earnings, recent strategic acquisitions, and positive product pipeline updates.&nbsp;</li></ul>Shares of pharmaceutical companies Kodiak Sciences Inc. (<a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a>), Repligen Corp. (RGEN) and Biogen Inc. (BIIB) surged to fresh 52-week highs on Monday amid positive trial results and strong earnings reports.&nbsp;<a href="https://stocktwits.com/symbol/KOD">KOD stock</a> surged more than 177% at close after it said that its experimental drugs, Zenkuda and KSI-501, had met the primary endpoints in its Phase 3 Daybreak trial.<a href="https://stocktwits.com/symbol/RGEN">RGEN stock</a> gained more than 2% at close, extending gains amid positive investor sentiment following its strong second-quarter 2026 earnings beat, increased full-year financial guidance, and expansion into cell therapy.<a href="https://stocktwits.com/symbol/BIIB">BIIB stock</a> gained about 0.5% at close on Monday amid a buy-in following its strong second-quarter 2026 earnings, recent strategic acquisitions, and positive product pipeline updates.&nbsp;<h2 class="st-heading-2">Kodiak Sciences Makes It To September’s Top Five Biotech Gainers</h2><a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a> stock jumped to a 52-week high of $95.77 on Monday, its steepest climb on record, after the company scored a major drug win.&nbsp;Kodiak&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/kod-stock-september-top-5-biotech-gainers-eye-drug-shkreli-still-sucks/cZMmZ2VRBXj">said</a> Monday that its two experimental therapies, Zenkuda and KSI-501, met the primary endpoints in the Phase 3 Daybreak trial, with both delivering vision improvements that were non-inferior to those seen with 2-mg aflibercept, the active ingredient in Regeneron’s original Eylea.&nbsp;The company reported no cases of intraocular inflammation in the Zenkuda arm and plans to seek regulatory approval in the fourth quarter, supported by positive data from five Phase 3 studies spanning three eye diseases.&nbsp;KSI-501, also known as Tabirafusp-ted, uses a different mechanism, and Kodiak plans additional analyses to determine whether certain wet AMD patients could benefit from its IL-6-targeting component. A separate Phase 3 study is evaluating KSI-501 in diabetic macular edema.On Stocktwits, retail sentiment around <a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a> stock was ‘extremely bullish’ at the time of writing. The company's shares have rallied more than 245% in 2026.&nbsp;<h2 class="st-heading-2">Repligen Extends Gains From Strong Quarter 2026&nbsp;</h2>RGEN stock climbed to a 52-week high of $198.87 on Monday, putting it on track for a sixth straight month of gains amid strong earnings, higher full-year guidance, and a major expansion into cell therapy.The company reported Q2 revenue of $204.1 million, up about 12% year over year, while adjusted earnings per share of $0.54 exceeded analyst expectations. Management subsequently raised its 2026 organic revenue-growth outlook to 10.5%-13.5% and increased adjusted EPS guidance to $2.03-$2.09.&nbsp;Repligen also recently agreed to acquire BioLife Solutions for approximately $1.5 billion, expanding its portfolio into cell-therapy biopreservation and strengthening its position in the growing cell and gene therapy market. The transaction is expected to broaden Repligen’s addressable market and add complementary products and capabilities.&nbsp;On Stocktwits, retail sentiment around RGEN stock was ‘bullish’ at the time of writing. The company's shares are up more than 18% this year.&nbsp;<h2 class="st-heading-2">Biogen Rises On The Back Of Strong Earnings, Positive Product Pipeline Updates</h2>BIIB stock rose to an annual high of $230.49 on Monday, putting it on track for a second consecutive month of gains as investors responded to strong second-quarter 2026 results, accelerating growth across its newer products and a series of pipeline and strategic developments.&nbsp;The company’s growth portfolio generated $1.06 billion in Q2 revenue, up 24% year-over-year, driven by continued launches and sales momentum for Skyclarys, Qalsody, Zurzuvae and Leqembi.Biogen also reported several pipeline catalysts. Leqembi received approval in Japan for a more convenient pen-based, at-home administration and a new formulation, Leqembi Iqlik.&nbsp;The company agreed to acquire RayThera for about $1 billion, strengthening its immunology portfolio, while Salanersen received FDA Breakthrough Therapy designation for spinal muscular atrophy.&nbsp;Biogen also highlighted encouraging clinical data for Zorevunersen in Dravet syndrome.On Stocktwits, retail sentiment around BIIB stock was ‘neutral’ at the time of writing. The company's shares have gained more than 28% in 2026.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Kodiak Sciences logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Biogen Inc

Kodiak Sciences Inc

Very bullish

Cautiously bullish

Cautiously bearish

Very bearish

Stocktwits sentiment on $SPY just hit its lowest level of the year. How are you feeling about the market right now?

Stocktwits

 just hit its lowest level of the year. How are you feeling about the market right now?

Current Price	$178.71
Prev Close	$180.01
Open	$179.45
Dividend Yield	0.00%
50-Day Moving Average	$176.91
Beta	1.43
Avg. Volume	1.07M
PE Ratio	243.57

52-Week High	$198.87
52-Week Low	$100.99
Market Capitalization	$11.35B
EPS (Annual)	$0.8644
Price to Book	4.77
Revenue Per Employee	$369,128.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

RGEN Fundamentals